Protara Therapeutics, Inc. (NASDAQ: TARA) had its price target raised by analysts at Oppenheimer Holdings Inc. from $26.00 to $30.00. They now have an "outperform" rating on the stock.
MediumReport
Protara Therapeutics, Inc. (NASDAQ: TARA) had its price target raised by analysts at Oppenheimer Holdings Inc. from $26.00 to $30.00. They now have an "outperform" rating on the stock.
Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
MediumReport
Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition [Yahoo! Finance]
HighReport
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition [Yahoo! Finance]
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: